ClinicalTrials.gg
RecruitingNCT06773091NKSOLIDUpdated Apr 6, 2026

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

A Phase 1 interventional study of NK042 and Fludarabine (FLU) in Advanced Solid Tumors, sponsored by Shanghai NK Cell Technology Co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Shanghai NK Cell Technology Co., LTD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors.

Read the detailed description

This study is divided into two phases: Phase Ia and Phase Ib.

Dose-Escalation and Expansion:

  • Phase Ia: This dose-escalation phase involves both single-dose and multiple-dose administrations of NK042 in patients with advanced solid tumors.
  • Phase Ib: This multiple-dose cohort-expansion phase will focus on solid tumor indications that demonstrated preliminary efficacy in Phase Ia.
02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • CAR-NK
  • Advanced solid tumors
  • Early-phase clinical trial
  • Cell Therapy
03

In context

Lead sponsor

This is the only study on the registry with Shanghai NK Cell Technology Co., LTD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signing of a written form.
  2. Age between 18 and 70 years.
  3. or cytologically confirmed locally advanced or solid tumor patients who are not amenable to surgical resection, with no standard treatment options, or who have or progressed after standard treatment, or are resistant or intolerant to standard treatment.
  4. At least one assessable tumor lesion according to , version 1.1 (RECIST 1.1).
  5. (ECOG) performance status score of 0-1.
  6. Expected survival ≥12 weeks.
  7. Must have adequate bone marrow, liver, and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Insufficient for prior anti-tumor treatments before the first dose, including chemotherapy, targeted therapy, antibody therapy, and radiotherapy.
  2. Participation in another clinical trial and use of drugs within 28 days before the first dose.
  3. Requirement for anticoagulation therapy.
  4. Symptomatic brain parenchymal with less than 4 weeks of stability after treatment.
  5. Active pulmonary diseases, including but not limited to interstitial lung disease, pneumonitis.
  6. Uncontrolled active infections.
  7. Uncontrollable massive pleural effusion, ascites, or pericardial effusion.
  8. Previous receipt of other cellular therapies.
  9. Planned concurrent participation in other anti-tumor treatments during the study.
  10. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    NK042 - cellular therapy

    Phase Ia (Dose Escalation): Determines maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) using single- and multiple-dose escalation with a "3+3" design. Phase Ib (Cohort Expansion): Evaluates safety, tolerability, and efficacy in solid tumor indications that demonstrated preliminary efficacy in Phase Ia. Participants undergo lymphodepletion prior to the first infusion of NK042.

    Biological: NK042 · Drug: Fludarabine (FLU) · Drug: Cyclophosphamide (CTX)

Interventions

  • BiologicalNK042

    NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors and enriched with NKR+ NK cells.

  • DrugFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs)

    Number of subjects experiencing adverse events, and the frequency and severity of adverse events. The type, frequency, onset, and severity of treatment-emergent adverse events (TEAEs) will be assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),version 5.0.

    Time frame: Up to 1 year after first dose of NK042.

  2. Dose Limiting Toxicities (DLTs)

    Identification of DLTs to determine the maximum tolerated dose (MTD).

    Time frame: Up to 28-day after first dose of NK042.

  3. Objective Response Rate (ORR)

    The proportion of participants achieving a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

    Time frame: Up to 1 year after first dose of NK042.

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Cmax of NK042 will be measured to determine the maximum concentration reached in the plasma following administration.

    Time frame: Predose, 4, 24, 48, 72, Day 8, Day 15, Day 22, Day 29 post-dose and every 2 months during the treatment follow-up period.

  2. Time to reach maximum concentration (Tmax)

    Tmax of NK042 will be assessed to determine the time point at which the highest plasma concentration is observed following administration.

    Time frame: Predose, 4, 24, 48, 72 hours, Day 8, Day 15, Day 22, Day 29 post-dose, and every 2 months during the treatment follow-up period.

  3. Area under the plasma concentration versus time curve (AUC₀-ₜ)

    AUC₀-ₜ will be assessed to determine the total NK042 exposure from the time of administration (0) to the last measurable concentration (t).

    Time frame: Predose, 4, 24, 48, 72 hours, Day 8, Day 15, Day 22, Day 29 post-dose, and every 2 months during the treatment follow-up period.

  4. Half-life (T₁/₂) of NK042

    T₁/₂ of NK042 will be assessed to determine the time required for a 50% reduction in the maximum amount of circulating NK042 in the plasma.

    Time frame: Predose, 4, 24, 48, 72 hours, Day 8, Day 15, Day 22, Day 29 post-dose, and every 2 months during the treatment follow-up period.

  5. Progression-Free Survival (PFS)

    The time from the first dose until objective tumor progression or death.

    Time frame: Up to 1 year after first dose of NK042 .

  6. Overall Survival (OS)

    The time from the first dose until death from any cause.

    Time frame: Up to 1 year after first dose of NK042 .

  7. Duration of Response (DOR)

    The time from the first documentation of CR or PR to disease progression or death.

    Time frame: Up to 1 year after first dose of NK042 .

  8. Disease Control Rate (DCR)

    The proportion of participants who achieve a CR, PR, or stable disease (SD) as assessed by RECIST 1.1.

    Time frame: Up to 1 year after first dose of NK042 .

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 14, 2025
StartActual
Feb 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06773091
Lead sponsor
Shanghai NK Cell Technology Co., LTD
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Feb 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Yongling Fu
Contact
yongling.fu@nk-celltech.com
+0086 02150888199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NK042

Start the discussion